Atypical Complications of Graves’ Disease: A Case Report and Literature Review

Table 1

Laboratory investigations at presentation and in the 3 months following carbimazole treatment.

	Presentation	Next day	2 weeks	3 months
TSH (mIU/L)	<0.01		<0.01	<0.01
FT4 (pmol/L)	54.69		23.99	6.6
FT3 (pmol/L)	>46.08		12.98	3.97
WBC (×10^9/L)	2.9	3.6	3.9	6.8
Neutrophils (×10^9/L)	1.1	2.2	2.1	3.8
Hemoglobin (g/L)	84	96	87	111
Hematocrit (%)	26.6	33.7	30.4	36.7
MCV (femtoliter)	83.1	91.9	92.3	89.1
Platelets (×10^9/L)	113	143	211	285
T. bilirubin (µmol/L)	35.3	31.1	21.9	11.7
D. bilirubin (µmol/L)	27.4	23.2	17.6	7.3
I. bilirubin (µmol/L)	6.9
ALP (U/L)	304	262	303	311
GGT (U/L)			128	98
ALT (U/L)	14	13	12	18
AST (U/L)	24	25	16	26
Albumin (g/L)	29	25	25	34
Weight (kg)	96			91

TSH: thyroid-stimulating hormone (0.45–4.5 mIU/L), FT4: free T4 (9–20 pmol/L), FT3: free T3 (2.6–5.7 pmol/L), WBC: white blood cells (4–10 × 10⁹/L), neutrophils (2–7 × 10⁹/L), hemoglobin (120–150 g/L), hematocrit (36–46%), MCV: mean corpuscular volume (83–101 femtoliter), platelets (150–400 × 10⁹/L), T. bilirubin: total bilirubin (3.4–20.5 µmol/L), D. bilirubin: direct bilirubin (0–8.6 µmol/L), I. bilirubin: indirect bilirubin (0–3 µmol/L), ALP: alkaline phosphatase (40–150 U/L), GGT: gamma-glutamyl transferase (9–36 U/L), ALT: alanine aminotransferase (0–55 U/L), AST: aspartate aminotransferase (5–34 U/L), albumin (35–50 g/L).